Sunday, February 21, 2016
Watchlist for Monday, February 22 $ADRO $VRNG $MVIS $ACHN $CHMA $SHAK $PRTA $NTAP $CMRX
The company announced in late December 2015 that brincidofovir didn't meet primary or secondary endpoints in the Phase 3 SUPRESS trial. But yesterday information provides an updated analysis of the Phase 3 results, which is clearly largely positive. Brincidofovir works and can save lives. They will meet with FDA again. Drug works. Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint!! Keep closely on the break above its 20EMA, could SkyRocket!!
All charts posted here are merely tools to study based on major technical indicators!! It is up to the reader to decide whether the stocks mentioned above are appropriate for your strategy! I warn that the good performance of a stock not depends only the technical data and I can not responsible for any trade that goes wrong!! Follow me on Twitter and Stocktwits, during the day I post some good ideas of trade